TerminatedNot Applicable

Swiss SOS MoCA - DCI Study

Stopped: COVID-restrictions on clinical research in Switzerland

Switzerland128 participantsStarted 2017-07-20

Plain-language summary

The primary objective of this multicenter observational study is to determine the effect size of the relationship between DCI and neuropsychological impairment 14-28 days and 3 months after aSAH. Secondary objectives are the feasibility to administer and the validity of the MoCA in an intensive care unit setting, as well as the test/retest reliability of the MoCA in patients with acute brain damage in absence of aSAH.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: For part 1 of the study: Participants fulfilling all of the following inclusion criteria are eligible for the study: * Consent of the patient or consent of patient's next of kin (plus consent of an independent physician if patient is unable to consent) * Aneurysmal SAH * Age: ≥18 * Time of aSAH known (IMPORTANT: at least approximated. Time of aSAH refers to the bleed that lead to hospital admission; warning leaks in the patient history are not considered aSAH in this context) * Complete aneurysm occlusion therapy within 48h after aSAH * Glasgow coma scale (GCS) ≥ 13 points at time point 48h - 72h after aSAH * Fluent language skills in either English, German, French, or Italian For part 2 of the study: Participants fulfilling all of the following inclusion criteria are eligible for the study: * Consent of the patient or consent of patient's next of kin (plus consent of an independent physician if patient is unable to consent) * Age: ≥18 * Acute brain injury that requires a in-patient treatment, e.g. for (surgical) treatment of a brain tumor, a cerebral hemorrhage, a hydrocephalus, stroke, or traumatic brain injury, with stable neurological and general health status * Glasgow coma scale (GCS) ≥ 13 points * Fluent language skills in either English, German, French, or Italian Exclusion Criteria: For part 1 of the study: The presence of any one of the following exclusion criteria will lead to exclusion of the participant: * SAH due to any other cause …

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Neuropsychological deterioration on the MoCA

Timeframe: 3 months after Subarachnoid Hemorrhage

Trial details

NCT IDNCT03032471

SponsorSwiss SOS Study Group

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-05-06

View on ClinicalTrials.gov More Subarachnoid Hemorrhage trials